OmniAb Inc
OABI1.380USD
-0.045-3.16%
Close 11/06, 16:00（ET）Quotes delayed by 15 min
198.66MMarket Cap
LossP/E TTM
More Details of OmniAb Inc Company
OmniAb, Inc. offers a discovery platform that provides pharmaceutical industry partners with access to diverse antibody repertoires and high-throughput screening technologies to enable the discovery of next-generation therapeutics. The OmniAb platform is the biological intelligence (BI) of transgenic animals, including OmniRat, OmniChicken, and OmniMouse, which have been genetically modified to generate antibodies with human sequences to facilitate the development of human therapeutic candidates. The Company’s OmniFlic (transgenic rat) and OmniClic (transgenic chicken) address industry needs for bispecific antibody applications through a common light chain approach, and OmniTaur features structural attributes of cow antibodies for complex targets. The Company's OmniChicken and OmniClic offer affinity-matured antibodies in an evolutionarily distant chicken host environment, which can deliver a diverse repertoire of antibody panels to conserved therapeutic target antigens.
OmniAb Inc Info
Ticker SymbolOABI
Company nameOmniAb Inc
IPO dateOct 09, 2020
CEOMr. Matthew William (Matt) Foehr
Number of employees114
Security typeOrdinary Share
Fiscal year-endOct 09
Address5980 Horton Street
CityEMERYVILLE
Stock exchangeNASDAQ Global Market Consolidated
CountryUnited States of America
Postal code94608
Phone15102507800
Websitehttps://www.omniab.com/
Ticker SymbolOABI
IPO dateOct 09, 2020
CEOMr. Matthew William (Matt) Foehr
Company Executives of OmniAb Inc
Name
Name/Position
Position
Shareholding
Change
Mr. John L. Higgins
Mr. John L. Higgins
Chairman of the Board
Chairman of the Board
2.85M
+0.71%
Mr. Kurt A. Gustafson
Mr. Kurt A. Gustafson
Executive Vice President - Finance, Chief Financial Officer
Executive Vice President - Finance, Chief Financial Officer
223.83K
-12.04%
Dr. Carolyn R. Bertozzi, Ph.D.
Dr. Carolyn R. Bertozzi, Ph.D.
Independent Director
Independent Director
93.31K
+23.52%
Mr. Steven (Steve) Love
Mr. Steven (Steve) Love
Independent Director
Independent Director
71.67K
+22.86%
Dr. Philip J. (Phil) Gotwals, Ph.D.
Dr. Philip J. (Phil) Gotwals, Ph.D.
Independent Director
Independent Director
--
--
Mr. Matthew William (Matt) Foehr
Mr. Matthew William (Matt) Foehr
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
--
--
Mr. Charles Stuart Berkman, J.D.
Mr. Charles Stuart Berkman, J.D.
Chief Legal Officer, Secretary
Chief Legal Officer, Secretary
--
--
Dr. Jennifer Cochran, Ph.D.
Dr. Jennifer Cochran, Ph.D.
Independent Director
Independent Director
--
--
Mr. Steven C. Crouse
Mr. Steven C. Crouse
Independent Director
Independent Director
--
--
Name
Name/Position
Position
Shareholding
Change
Mr. John L. Higgins
Mr. John L. Higgins
Chairman of the Board
Chairman of the Board
2.85M
+0.71%
Mr. Kurt A. Gustafson
Mr. Kurt A. Gustafson
Executive Vice President - Finance, Chief Financial Officer
Executive Vice President - Finance, Chief Financial Officer
223.83K
-12.04%
Dr. Carolyn R. Bertozzi, Ph.D.
Dr. Carolyn R. Bertozzi, Ph.D.
Independent Director
Independent Director
93.31K
+23.52%
Mr. Steven (Steve) Love
Mr. Steven (Steve) Love
Independent Director
Independent Director
71.67K
+22.86%
Dr. Philip J. (Phil) Gotwals, Ph.D.
Dr. Philip J. (Phil) Gotwals, Ph.D.
Independent Director
Independent Director
--
--
Mr. Matthew William (Matt) Foehr
Mr. Matthew William (Matt) Foehr
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
--
--
Revenue Breakdown
Currency: USDUpdated: Mon, Oct 6
Currency: USDUpdated: Mon, Oct 6
FY2025Q2
FY2025Q1
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2022Q1
FY2021
FY2020
FY2019
By BusinessUSD
Name
Revenue
Proportion
Service revenue
1.94M
49.68%
License and milestone revenue
1.24M
31.87%
xPloration revenue
608.00K
15.60%
Royalty revenue
111.00K
2.85%
No Data
By Business
By Region
By BusinessUSD
Name
Revenue
Proportion
Service revenue
1.94M
49.68%
License and milestone revenue
1.24M
31.87%
xPloration revenue
608.00K
15.60%
Royalty revenue
111.00K
2.85%
Shareholding Stats
Updated: Mon, Sep 8
Updated: Mon, Sep 8
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
Avista Capital Holdings, LP
10.99%
Whitefort Capital Management, LP
7.11%
Ash X LP
5.75%
BlackRock Institutional Trust Company, N.A.
4.40%
The Vanguard Group, Inc.
3.66%
Other
68.09%
Shareholders
Shareholders
Proportion
Avista Capital Holdings, LP
10.99%
Whitefort Capital Management, LP
7.11%
Ash X LP
5.75%
BlackRock Institutional Trust Company, N.A.
4.40%
The Vanguard Group, Inc.
3.66%
Other
68.09%
Shareholder Types
Shareholders
Proportion
Investment Advisor
16.23%
Hedge Fund
14.30%
Private Equity
12.89%
Investment Advisor/Hedge Fund
12.76%
Corporation
8.21%
Individual Investor
6.69%
Research Firm
1.01%
Pension Fund
0.14%
Venture Capital
0.11%
Other
27.66%
Institutional Shareholding
Updated: Wed, Oct 1
Updated: Wed, Oct 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q3
349
70.66M
57.59%
-18.22M
2025Q2
348
92.68M
75.53%
-5.84M
2025Q1
359
87.33M
71.43%
-8.58M
2024Q4
365
89.85M
74.79%
-8.38M
2024Q3
394
90.25M
75.21%
-25.05M
2024Q2
389
89.07M
76.08%
-29.09M
2024Q1
378
93.24M
79.93%
-23.55M
2023Q4
374
92.06M
79.14%
-28.03M
2023Q3
352
92.71M
80.23%
-26.22M
2023Q2
337
91.30M
79.07%
-24.17M
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
Avista Capital Holdings, LP
15.82M
12.89%
--
--
Sep 30, 2024
Whitefort Capital Management, LP
10.24M
8.35%
+6.33M
+161.57%
Jun 30, 2025
Ash X LP
8.27M
6.74%
+2.86M
+52.77%
Aug 26, 2025
BlackRock Institutional Trust Company, N.A.
6.33M
5.16%
-122.32K
-1.89%
Jun 30, 2025
The Vanguard Group, Inc.
5.27M
4.29%
+89.01K
+1.72%
Jun 30, 2025
Foehr (Matthew W)
4.34M
3.53%
+540.54K
+14.24%
Aug 26, 2025
Dimensional Fund Advisors, L.P.
2.91M
2.37%
-217.95K
-6.96%
Jun 30, 2025
Higgins (John L)
2.85M
2.32%
+20.00K
+0.71%
Jun 17, 2025
Private Management Group, Inc.
2.56M
2.08%
+28.29K
+1.12%
Jun 30, 2025
Geode Capital Management, L.L.C.
2.44M
1.99%
-21.63K
-0.88%
Jun 30, 2025
View more
Related ETFs
Updated: Thu, Nov 6
Updated: Thu, Nov 6
Name
Proportion
iShares Micro-Cap ETF
0.03%
Goldman Sachs ActiveBeta US Small Cap Equity ETF
0.02%
ProShares Ultra Nasdaq Biotechnology
0.02%
Invesco Nasdaq Biotechnology ETF
0.02%
Invesco RAFI US 1500 Small-Mid ETF
0.01%
Proshares Ultra Russell 2000
0.01%
ProShares UltraPro Russell2000
0.01%
Fidelity Enhanced Small Cap ETF
0.01%
Global X Russell 2000 ETF
0.01%
iShares Russell 2000 Value ETF
0.01%
View more
iShares Micro-Cap ETF
Proportion0.03%
Goldman Sachs ActiveBeta US Small Cap Equity ETF
Proportion0.02%
ProShares Ultra Nasdaq Biotechnology
Proportion0.02%
Invesco Nasdaq Biotechnology ETF
Proportion0.02%
Invesco RAFI US 1500 Small-Mid ETF
Proportion0.01%
Proshares Ultra Russell 2000
Proportion0.01%
ProShares UltraPro Russell2000
Proportion0.01%
Fidelity Enhanced Small Cap ETF
Proportion0.01%
Global X Russell 2000 ETF
Proportion0.01%
iShares Russell 2000 Value ETF
Proportion0.01%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
No Data
Date
Type
Ratio
No Data
